부산대학교 도서관

A number of anti-osteoporotic drugs, predominantly inhibitors of bone resorption, are currently used in the management of patients with osteoporosis to reduce the risk of fractures. While the management of the disease has improved significantly, there are still unmet needs, mainly due to a lack of agents able to replace bone that has already been lost. Human and animal genetics have identified the pivotal role of the Wnt signaling pathway in the regulation of bone formation by the osteoblasts and have made it a very attractive target for the development of novel treatments for osteoporosis. In this article, we review evidence that supports the targeting of components of the Wnt signaling pathway for the design of bone-forming treatments for osteoporosis.
Author(s): Maria P Yavropoulou [sup.1] , Socrates E Papapoulos [sup.[[dagger]]] [sup.2] Keywords: novel treatments; osteoporosis; sclerostin; Wnt signaling Osteoporosis is a common chronic disease characterized by low bone mass and [...]